The England National Health Service (NHS) is the world's first healthcare system to offer a revolutionary blood cancer treatment called a "Trojan horse" drug. The trailblazing treatment, officially known as belantamab mafodotin, has the potential to add years to the lives of thousands of patients fighting multiple myeloma, a vicious and currently untreatable form of bone marrow cancer.

This innovation, now being rolled out to eligible patients throughout England, highlights the revolutionary promise of precision medicine and targeted treatments to change cancer care.

How Does This Therapy Work?

At the center of this medical innovation is belantamab mafodotin, also known as Blenrep and produced by GlaxoSmithKline. In contrast to traditional chemotherapy that gets into both healthy and cancer cells, this new medication uses a targeted approach: it binds to myeloma cells, enters them quietly, and delivers a fatal dose of chemotherapy directly within, effectively killing the malignancy from the inside out.

This "Trojan horse" metaphor comes from Greek mythology, as Greek warriors entered the city of Troy disguised within a wooden horse. In the same way, this drug corrupts cancer cells by smuggling a toxic payload into them disguised as an antibody—spared most healthy tissues in the process.

NHS England National Clinical Director for Cancer Professor Peter Johnson called the treatment "life-changing" and said, "Myeloma is an aggressive blood cancer, but the advent of belantamab mafodotin brings with it a new hope of highly extended disease control.

Multiple myeloma is a plasma cancer that arises in plasma cells present in the bone marrow. Although there are continued advances in medicine, the disease is still incurable and relapsing in nature. The majority of patients have a pattern of recurrence after remission, requiring multiple treatment lines.

Trials of belantamab mafodotin, particularly in combination with other drugs such as bortezomib and dexamethasone, have shown that the treatment can stop disease from progressing for a period of three years—three years longer than the 13-month postponement achieved with the drug of choice at present, daratumumab.

The National Institute for Health and Care Excellence (NICE), having checked the effectiveness and value for money, accelerated approval for the rollout of the treatment. NICE director Helen Knight stated, "This recommendation shows our determination to get patients the best treatment quickly while protecting value for the taxpayer."

Who Will Benefit?

The NHS rollout will first address about 1,500 patients per year in England that have relapsed or are resistant to their existing treatments. These are often those with advanced myeloma who have run out of other standard treatments.

Significantly, this represents a move toward personalized, next-generation treatments being accessible through public healthcare facilities—an accomplishment welcomed by health activists and oncologists alike.

Shelagh McKinlay, Myeloma UK's Director of Research and Advocacy, hailed the announcement: "We have campaigned aggressively for the last year to get this drug approved. It will change the lives of thousands of myeloma patients."

Paul Silvester, who is 60 and from Sheffield, was diagnosed with multiple myeloma in 2023. When ordinary treatment and even a bone marrow transplant did not halt the disease, he was put on an early-access trial for belantamab mafodotin at the Royal Hallamshire Hospital.

The change was almost instant," he explained. "In the first two or three weeks following the first dose, I was in remission. I like to think this treatment has brought the party balloons into the house."

Paul is now in remission and mapping out history-themed travel excursions—something he never thought he'd ever be able to do a few months ago.

How Does Belantamab Mafodotin Work?

Belantamab mafodotin is an antibody-drug conjugate (ADC), a new class of cancer drugs. The drug's antibody component targets a protein (BCMA) on the outside of myeloma cells. After binding to the cancer cell, the complex is taken into the cell where it drops off a potent chemotherapy drug, essentially killing it from within.

This internal targeting results in much less collateral damage to normal cells—a major problem with standard chemotherapy—and decreases the overall treatment burden.

Side Effects and Safety Issues

Although thought to be less toxic than many standard therapies, belantamab mafodotin is not without adverse effects. Patients can have dry eyes, blurred vision, and occasionally more severe ocular toxicity due to the mechanism of action of the drug leaking into surrounding tissues after cell kill.

Clinical teams are trained to monitor and manage these effects, often adjusting dosage or incorporating supportive therapies to preserve patient safety.

Health Minister Karin Smyth emphasized the significance of this development: “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”

In fact, the move by the NHS to be the first healthcare system in the world to introduce this treatment establishes a precedent for the incorporation of high-cost, high-impact biologic therapies into national care.

With its effective implementation in England, belantamab mafodotin could soon be used as a worldwide standard of care for relapsed or refractory multiple myeloma. As other nations observe outcomes and cost-effectiveness trends, it is possible that health systems globally will look into implementing this Trojan horse technique.

Researchers in oncology are also looking at similar antibody-drug conjugates for other types of cancer, including breast, lung, and ovarian cancers—implying that we are just beginning to see what this technology has to give.

Health authorities in the UK have reported a significant rise in chikungunya cases, a mosquito-borne disease known for causing severe joint pain that can leave sufferers hunched over. Between January and June 2025, there were 73 confirmed cases in England, Wales, and Northern Ireland, more than double the 27 recorded during the same period in 2024. The UK Health Security Agency (UKHSA) says this is the highest number ever recorded, with nearly all linked to overseas travel.

What is Chikungunya?

Spread by the bite of infected Aedes mosquitoes, particularly the Aedes aegypti and Aedes albopictus species, chikungunya is not usually deadly but can be devastating for the very young, the elderly, or those with underlying health conditions.

Typical symptoms include:

• Excruciating joint pain that can leave sufferers bent over in agony
• High fever and headaches
• Muscle aches and swelling in the joints (especially hands and feet)
• Nausea, fatigue, and a rash that’s red, bumpy, and decidedly not Instagrammable

In severe cases, the arthritis-like pain can linger for months or even years, turning every movement into a reminder that mosquitoes are not just a mild holiday nuisance.

The majority of UK cases this year were linked to travel to Sri Lanka, India, and Mauritius. All were reported in England, with London taking the dubious honour of having the most cases. However, the two mosquito species that spread the virus are not established in the UK, so there is no risk of it transmitting locally.

UK logs first cases of oropouche virus

As if one virus was not enough, the UK has also logged its first cases of the oropouche virus, also dubbed ‘sloth fever’. This one circulates in the wild between primates, sloths, and birds before occasionally hopping over to humans via midges or mosquitoes.

Found primarily in the Amazon basin, oropouche has recently started wandering further across the Americas. All the UK cases were linked to travel from Brazil, so unless your staycation involves tree-dwelling mammals and tropical insects, you are safe for now.

The Global Bug Crawl

Chikungunya is typically found in Africa and southern Asia, but 2025 has seen it pop up in unexpected places. Outbreaks have been reported in China, the Indian Ocean islands of Reunion, Mayotte and Mauritius, and across the Americas. In southern China, more than 7,000 people have been infected since June, prompting COVID-style lockdowns in Foshan and at least a dozen other cities in Guangdong province. Hong Kong and Taiwan have also reported cases.

Health officials are urging travellers to take bite prevention seriously.

How to safeguard against mosquito bites

According to the US Centres for Disease Control and Prevention (CDC), your best defence is to stop mosquitoes from making contact in the first place.

Top tips include:

• Use Environmental Protection Agency (EPA)-registered insect repellent
• Wear long-sleeved shirts and trousers (mosquitoes can’t bite what they can’t reach)
• Treat clothing and gear with 0.5% permethrin for extra armour
• Choose accommodation with air conditioning or window screens
• If sleeping outdoors, use a mosquito net unless you enjoy sharing your bed with the local insect population

Vaccination

In addition to covering up and dousing yourself in repellent, some travellers may be advised to get the chikungunya vaccine before heading to certain destinations. Your healthcare provider can help you decide if this applies to your travel plans.

Why the Surge Now?

Several factors could be behind the sharp rise in cases. Increased international travel post-pandemic, changing weather patterns favouring mosquito breeding, and outbreaks in popular holiday destinations have created a perfect storm. Mosquitoes thrive in warm, wet conditions, and with climate change extending those conditions into more regions, these viruses are no longer staying politely within their old borders.

Chikungunya virus can turn a dream getaway into a painful endurance test, and once contracted, it is all about managing symptoms; there is no cure. The same goes for oropouche: prevention is your best friend. In the world of tropical diseases, an ounce of repellent really is worth a pound of cure.

Scott Swift, 73, pop singer Taylor Swift's dad just underwent a quintuple bypass surgery, revealed Taylor during one of the episodes of Travis Kelce and Jason Kelce's New Heights podcast.

She also shared that she had moved in with her dad earlier this year to take care of him for a speedy recovery. She noted that her father has been full of gratitude after the surgery. "He was the loveliest patient ever. He just kept saying thank you over and over again."

Why Did Scott Swift Need A Surgery?

Taylor called the surgery "really intense" and said that her dad's heart always had a healthy ECG or electrocardiogram. He also ensures to get it every year to remain a step ahead of any physical ailments. However, five hard blockages were found in his heart during a resting stress test.

"He's been telling all his friends, 'You need to get the stress test,' because that's what's actually preventative. If you can find that earlier, you don't have to have a bypass surgery," she said.

Taylor confirmed that her father is doing "incredibly well" and that his humor has helped him go through during the hard times. It still is very much intact in him.

She shares that he did not know how many blockages he's had, on being told that he underwent a quintuple bypass, which means five blockages, he also joked about it. "Well, you see, I come from a very competitive family," he told Taylor.

What Is A Stress Test?

As per the National Institute of Health (NIH), US, it is a form of physical test that typically utilizes electrocardiography along with blood pressure monitoring and exercise, which involves a treadmill or bicycle.

However, in a resting stress test, the assessment happens when the heart muscle is at rest after stress. This stress helps in identifying areas of reduced blood flow like ischemia or damage to the heart muscle, which can indicate conditions like coronary artery disease.

The test involves injecting a radioactive tracer into the bloodstream, then using a special camera to take images of the heart at rest and after stress.

What Is A Bypass Surgery?

As per Johns Hopkins Medicine, bypass surgery or coronary artery bypass graft surgery (CABG) is a procedure used to treat coronary artery disease. Coronary artery disease (CAD) is the narrowing of the coronary arteries. These are the blood vessels that supply oxygen and nutrients to the heart muscle. CAD is caused by a build-up of fatty material within the walls of the arteries. This buildup narrows the inside of the arteries, limiting the supply of oxygen-rich blood to the heart muscle.

How Does It Work?

One way to treat the blocked or narrowed arteries is to bypass the blocked portion of the coronary artery with a piece of a healthy blood vessel from elsewhere in your body. Blood vessels, or grafts, used for the bypass procedure may be pieces of a vein from your leg or an artery in your chest. An artery from your wrist may also be used.

ALSO READ: 4 Rare Heart Diseases That Are Becoming Common By Each Passing Day

This surgery is done to treat a blockage or narrowing of one or more of the coronary arteries. It can restore the blood supply to your heart muscle when nonsurgical procedures are not a choice.

More Updates From The Swift Family

In addition to Scott, Taylor shared that her mom Andrea Swift, too, under a procedure. “My mom just got a new knee,” Taylor shared. “She’s doing great. She’s scampering around. We’re not quite at scampering yet, but she’s doing great.”

She noted that her parents are her best friends.

"It was actually one of the most special things that's ever happened to me, spending all that time with them this summer. You have those long talks that you don't have when it's a small, concentrated period of time.”

The U.S. Food and Drug Administration (FDA) has announced that the nationwide shortage of sodium chloride 0.9 percent intravenous (IV) saline solution, which is a critical medical supply used in hospitals and emergency care, has officially come to an end. The resolution marks a significant milestone in stabilizing the supply of one of the most essential tools in patient care.

Collaborative Effort to Restore Supply

FDA Commissioner Marty Makary, M.D., M.P.H., credited the resolution of the shortage to a coordinated effort between the FDA, the Administration for Strategic Preparedness and Response (ASPR), and industry partners. According to Makary, this multi-agency and cross-sector collaboration allowed for rapid action to address the supply gap that had strained healthcare facilities across the country.

To overcome the shortage, the FDA and its partners implemented several urgent measures. These included enabling the temporary import of IV saline solutions from approved international sources, expediting the review process for domestic manufacturing expansions, and extending expiry dates for existing products after rigorous safety assessments. This combination of strategies helped boost production capacity and prevent supply chain bottlenecks.

Impact on Hospitals and Patient Care

Sodium chloride 0.9 percent IV saline is used for hydration, administering medications, and treating dehydration and other critical conditions. The shortage, which had persisted for months, forced hospitals to ration supplies and find alternative solutions. Medical professionals often had to adjust treatment protocols or use smaller IV bags to stretch resources, a situation that placed additional strain on already burdened healthcare systems.

Now, with supplies back to normal levels, the FDA has confirmed that the product will be removed from its official Drug Shortage Database. Facilities are being advised to return to using FDA-approved products whenever available.

ALSO READ: The Truth About IV Drips: Are They Better Than Food Or Supplements?

Ongoing Efforts to Prevent Future Shortages

While celebrating the resolution, the FDA emphasized that its work to secure medical product availability is far from over. Makary stressed that the agency remains committed to addressing other ongoing shortages, including those affecting certain IV fluids.

“The FDA remains focused on doing all we can to help mitigate shortages and prevent them from occurring,” Makary said in a statement. “We will continue working diligently to monitor supply levels, anticipate potential disruptions, and support a robust, secure, and transparent supply chain for medical products.”

The agency’s strategy involves close monitoring of manufacturer reports, collaboration with other federal agencies, and engagement with the private sector to anticipate challenges before they escalate into full-scale shortages.

A Model for Crisis Response

Experts say the resolution of the saline shortage could serve as a model for responding to future disruptions in medical supply chains. By acting quickly, coordinating with multiple stakeholders, and making temporary regulatory adjustments, the FDA and its partners were able to restore availability without compromising patient safety.

Public health advocates note that the success also underscores the importance of maintaining diverse manufacturing sources, both domestically and internationally, to safeguard against sudden disruptions caused by disasters, supply chain issues, or unexpected surges in demand.

The FDA’s announcement brings relief to healthcare providers nationwide, who have been navigating supply constraints for essential items over the past few years. With IV saline now in stable supply, hospitals can focus more on patient care without the added stress of product scarcity.

However, the agency cautions that vigilance is essential. The FDA will continue to work with manufacturers, monitor production levels, and apply lessons learned from this shortage to strengthen the overall resilience of the nation’s medical supply system.